Management Considerations for the COVID-19 Patient with Severe Disease: A Case Scenario and Literature Review

Alhazzani W Møller MH Arabi YM Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Intensive Care Med. 2020 46854–88710.1007/s00134-020-06022-5

Alía I Esteban A Correction: Weaning from mechanical ventilation J Crit Care. 2006 10 4 414 10.1186/cc4996

Amato MB Barbas CS Medeiros DM Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome N Engl J Med. 1998 338347–354 1:STN:280:DyaK1c7ht1ejtw%3D%3D 10.1056/NEJM199802053380602

Baig AM Khaleeq A Ali U Syeda H Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms ACS Chem Neurosci. 2020 11 7995–998 1:CAS:528:DC%2BB3cXkslGrs70%3D 10.1021/acschemneuro.0c00122 32167747 7094171

Beigel JH , Tomashek KM , Dodd LE , et al. Remdesivir for the treatment of Covid-19—preliminary report [published online ahead of print, 2020 May 22]. N Engl J Med. 2020;https://doi.org/10.1056/NEJMoa2007764.

Bernard GR Artigas A Brigham KL The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination Am J Respir Crit Care Med. 1994 149 3 pt 1818–824 1:STN:280:DyaK2c7mtlCnsA%3D%3D 10.1164/ajrccm.149.3.7509706

Bhimraj A , Morgan R , Shumacker A , et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. 2020. Available from https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#toc-3.

Boussuges A Blanc P Molenat F Evaluation of left ventricular filling pressure by transthoracic Doppler echocardiography in the intensive care unit Crit Care Med. 2002 30362–36710.1097/00003246-200202000-00016

Brower R Matthay M Morris A Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome N Engl J Med. 2000 3421301–130810.1056/NEJM200005043421801

Cao B Wang Y Wen D A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 N Engl J Med. 2020 382 191787–179910.1056/NEJMoa200128232187464

Carod-Artal FJ Neurological complications of coronavirus and COVID-19. Complicaciones neurológicas por coronavirus y COVID-19 Rev Neurol 2020 70 9311–322 1:STN:280:DC%2BB38zptVKhsw%3D%3D 10.33588/rn.7009.202017932329044

Choy KT Wong AY Kaewpreedee P Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro Antiviral Res. 2020 178104786 1:CAS:528:DC%2BB3cXntVOhtLw%3D 10.1016/j.antiviral.2020.104786 32251767 7127386

Combes A Hajage D Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome N Engl J Med. 2018 378 211965–197510.1056/NEJMoa1800385

Connors JM Levy JH COVID-19 and its implications for thrombosis and anticoagulation Blood. 2020 135 232033–2040 1:CAS:528:DC%2BB3cXhtlSjs7nJ 10.1182/blood.2020006000 32339221 7273827

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Interleukin-6 inhibitors. National Institutes of Health. Available from https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/interleukin-6-inhibitors/. Accessed 29 May 2020.

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Antithrombotic therapy in patients with COVID-19. National Institutes of Health. Available from https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/antithrombotic-therapy/. Accessed 29 May 2020.

Durvasula R Wellington T McNamara E Watnick S COVID-19 and kidney failure in the acute care setting: our experience from Seattle Am J Kidney Dis. 2020 76 14–6 1:CAS:528:DC%2BB3cXotFCgurw%3D 10.1053/j.ajkd.2020.04.001 32276031 7141473

Famous KR Delucchi K Ware LB Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy Am J Respir Crit Care Med. 2017 195331–338 1:CAS:528:DC%2BC1cXjt1Sltbo%3D 10.1164/rccm.201603-0645OC

Filatov A Sharma P Hindi F Espinosa PS Neurological complications of coronavirus disease (COVID-19): encephalopathy Cureus. 2020 12 3e735210.7759/cureus.7352 32328364 7170017

Gattinoni L Chiumello D Caironi P COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 46 61099–1102 1:CAS:528:DC%2BB3cXnsVait70%3D 10.1007/s00134-020-06033-232291463

Gautret P Lagier JC Parola P Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Int J Antimicrob Agents. 2020 56 1105949 1:CAS:528:DC%2BB3cXhsVOqt7vE 10.1016/j.ijantimicag.2020.105949 32205204 7102549

Geleris J Sun Y Platt J Observational study of hydroxychloroquine in hospitalized patients with Covid-19 N Engl J Med. 2020 382 252411–2418 1:CAS:528:DC%2BB3cXht1Gmsb3N 10.1056/NEJMoa2012410

Gilead Pharmaceuticals. Gilead presents additional data on investigational antiviral remdesivir for the treatment of COVID-19 [press release]. 10 July 2020. Available from https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19. Accessed 31 July 2020.

Goldman JD , Lye DCB , Hui DS , et al. Remdesivir for 5 or 10 days in patients with severe Covid-19 [published online ahead of print, 2020 May 27]. N Engl J Med. 2020;NEJMoa2015301. https://doi.org/10.1056/NEJMoa2015301.

Gordon DE Jang GM Bouhaddou M A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Nature. 2020 583 7816459–468 1:CAS:528:DC%2BB3cXhtlCqtbrI 10.1038/s41586-020-2286-9 32353859 7431030

Goyal P Choi JJ Pinheiro LC Clinical characteristics of Covid-19 in New York City N Engl J Med. 2020 382 242372–237410.1056/NEJMc201041932302078

Guan W Ni Z Hu Y Clinical characteristics of coronavirus disease 2019 in China N Engl J Med. 2020 382 181708–1720 1:CAS:528:DC%2BB3cXovVSjsb8%3D 10.1056/NEJMoa200203232109013

Guérin C Reignier J Richard J Prone positioning in severe acute respiratory distress syndrome N Engl J Med. 2013 368 232159–216810.1056/NEJMoa1214103

Helms J Kremer S Merdji H Neurologic features in Severe SARS-CoV-2 infection N Engl J Med. 2020 382 232268–227010.1056/NEJMc200859732294339

Helms J Tacquard C Severac F High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Intensive Care Med. 2020 46 61089–1098 1:CAS:528:DC%2BB3cXosVyktbc%3D 10.1007/s00134-020-06062-x

Henry BM Lippi G Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports J Crit Care. 2020 5827–28 1:CAS:528:DC%2BB3cXmvFGqt7Y%3D 10.1016/j.jcrc.2020.03.011

Hung IF Lung KC Tso EY Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Lancet. 2020 395 102381695–1704 1:CAS:528:DC%2BB3cXovFOjsr0%3D 10.1016/S0140-6736(20)31042-4 32401715 7211500

Jin M Tong Q Rhabdomyolysis as potential late complication associated with 2019 novel coronavirus disease Emerg Infect Dis. 2020 26 71618–1620 1:CAS:528:DC%2BB3cXitlOlsbvM 10.3201/eid2607.200445 32197060 7323559

Kim D , Quinn J , Pinsky B , Shah NH , Brown I . Rates of co-infection between SARS-CoV-2 and other respiratory pathogens [published online ahead of print, 2020 Apr 15]. JAMA. 2020;323(20):2085–2086. https://doi.org/10.1001/jama.2020.6266.

Kimmig L , Wu D , Gold M , et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections [preprint posted online, 2020 May 20]. medRxiv. 2020. 05.15.20103531. https://doi.org/10.1101/2020.05.15.20103531.

Kindler E Thiel V Weber F Interaction of SARS and MERS coronaviruses with the antiviral interferon response Adv Virus Res. 2016 96219–243 1:CAS:528:DC%2BB3cXhsFGrtrnM 10.1016/bs.aivir.2016.08.006 27712625 7112302

Klok FA Kruip MJHA van der Meer NJM Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thromb Res. 2020 191145–147 1:CAS:528:DC%2BB3cXntVOjs7k%3D 10.1016/j.thromres.2020.04.013 32291094 7146714

Lax SF , Skok K , Zechner P , et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series [published online ahead of print, 2020 May 14]. Ann Intern Med. 2020;M20-2566. https://doi.org/10.7326/M20-2566.

Li X Guo Z Li B Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China ASAIO J. 2020 66 5475–481 1:CAS:528:DC%2BB3cXnvFKltbg%3D 10.1097/MAT.0000000000001172 32243266 7273861

Liu J Cao R Xu M Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Cell Discov 2020 616 1:CAS:528:DC%2BB3cXltFChsrc%3D 10.1038/s41421-020-0156-0 32194981 7078228Published 2020 Mar 18

Maatman TK , Jalali F , Feizpour C , et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019 [published online ahead of print, 2020 May 27]. Crit Care Med. 2020. https://doi.org/10.1097/CCM.0000000000004466.

Mahévas M Tran VT Roumier M Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data [published correction appears in BMJ. 2020 Jun 18;369:m2328] BMJ 2020 369m184410.1136/bmj.m1844 32409486 7221472

Mao L Jin H Wang M Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China [published online ahead of print, 2020 Apr 10] JAMA Neurol. 2020 77 61–910.1001/jamaneurol.2020.11277149362

Marini JJ , Gattinoni L . Management of COVID-19 respiratory distress [published online ahead of print, 2020 Apr 24]. JAMA. 2020;https://doi.org/10.1001/jama.2020.6825.

Massachusetts General Hospital. Hematology recommendations and dosing guidelines during COVID-19. 2020 Apr 30. Available from https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guidance-from-mass-general-hematology.pdf. Accessed 31 July 2020.

Mauri T , Spinelli E , Scotti E , et al. Potential for lung recruitment and ventilation-perfusion mismatch in patients with the acute respiratory distress syndrome from coronavirus disease 2019 [published online ahead of print, 2020 Apr 17]. Crit Care Med. 2020. https://doi.org/10.1097/CCM.0000000000004386.

Mehta P McAuley D Brown M COVID-19: consider cytokine storm syndromes and immunosuppression Lancet. 2020 395 102291033–1034 1:CAS:528:DC%2BB3cXltFCjsb8%3D 10.1016/S0140-6736(20)30628-0 32192578 7270045

Montalvan V Lee J Bueso T De Toledo J Rivas K Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review Clin Neurol Neurosurg. 2020 194105921 1:STN:280:DC%2BB38votlygtg%3D%3D 10.1016/j.clineuro.2020.105921 32422545 7227498

Moriguchi T Harii N Goto J A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 Int J Infect Dis. 2020 9455–58 1:CAS:528:DC%2BB3cXnsVajtLg%3D 10.1016/j.ijid.2020.03.062 32251791 7195378

Moss JH Lanctôt KL Iatrogenic benzodiazepine withdrawal delirium in hospitalized older patients J Am Geriatr Soc. 1998 46 81020–1022 1:STN:280:DyaK1czntVeqsA%3D%3D 10.1111/j.1532-5415.1998.tb02761.x9706895

Nile SH Nile A Qiu J Li L Jia X Kai G COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons Cytokine Growth Factor Rev. 2020 5366–70 1:CAS:528:DC%2BB3cXpsVKrsLs%3D 10.1016/j.cytogfr.2020.05.002 32418715 7204669

Pisani MA Murphy TE Araujo KL Slattum P Van Ness PH Inouye SK Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population Crit Care Med. 2009 37 1177–183 1:CAS:528:DC%2BD1cXhsFCnu7vE 10.1097/CCM.0b013e318192fcf9 19050611 2700732

Poyiadji N Shahin G Noujaim D Stone M Patel S Griffith B COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features Radiology. 2020 296 2E119–E12010.1148/radiol.202020118732228363

Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir. No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY. 29 June 2020. Available from https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery. Accessed 31 July 2020.

Ranieri VM Suter PM Tortorella C Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial JAMA. 1999 28254–61 1:STN:280:DyaK1MzjtFOqug%3D%3D 10.1001/jama.282.1.54

Ranucci M Ballotta A Di Dedda U The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome J Thromb Haemost. 2020 18 71747–1751 1:CAS:528:DC%2BB3cXhtlehu7%2FF 10.1111/jth.1485432302448

RECOVERY Collaborative Group, Horby P , Lim WS , et al. Dexamethasone in hospitalized patients with Covid-19-preliminary report [published online ahead of print, 2020 Jul 17]. N Engl J Med.2020;NEJMoa2021436. https://doi.org/10.1056/NEJMoa2021436

Riva L , Yuan S , Yin X , et al. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals [preprint published online 2020 Apr 16]. bioRxiv. 2020;2020.04.16.044016. https://doi.org/10.1101/2020.04.16.044016.

Russell CD Millar JE Baillie JK Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Lancet. 2020 395 10223473–475 1:CAS:528:DC%2BB3cXisFaksr4%3D 10.1016/S0140-6736(20)30317-2 32043983 7134694

Searcy RJ Morales JR Ferreira JA The role of inhaled prostacyclin in treating acute respiratory distress syndrome Ther Adv Respir Dis. 2015 9302–312 1:CAS:528:DC%2BC28XnslOkt74%3D 10.1177/1753465815599345

Sedaghat Z Karimi N Guillain Barre syndrome associated with COVID-19 infection: A case report J Clin Neurosci. 2020 76233–235 1:CAS:528:DC%2BB3cXns1WrsL4%3D 10.1016/j.jocn.2020.04.062 32312628 7158817

Steardo L Steardo L Zorec R Verkhratsky A Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19 Acta Physiol (Oxf). 2020 229 3e13473 1:CAS:528:DC%2BB3cXmvVCgsbg%3D 10.1111/apha.1347332223077

Supady A. Cytokine adsorption in severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV) [clinical trial: NCT04324528]. Available from https://www.clinicaltrials.gov/ct2/show/NCT04324528?term=cytosorb&cond=Coronavirus&draw=2&rank=1.

Synairgen. Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients [press release]. 20 July 2020. Available from https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf. Accessed 31 July 2020.

Tang N Li D Wang X Sun Z Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia J Thromb Haemost. 2020 18844–847 1:CAS:528:DC%2BB3cXlvV2ns70%3D 10.1111/jth.14768 32073213 7166509

Tang W Cao Z Han M Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial BMJ. 2020 369m184910.1136/bmj.m1849 32409561 7221473

Thachil J Tang N Gando S ISTH interim guidance on recognition and management of coagulopathy in COVID-19 J Thromb Haemost. 2020 181023–1026 1:CAS:528:DC%2BB3cXotlSjsrk%3D 10.1111/jth.1481032338827

Tisoncik JR Korth MJ Simmons CP Into the eye of the cytokine storm Microbiol Mol Biol Rev. 2012 76 116–32 1:CAS:528:DC%2BC38XlslKisb4%3D 10.1128/MMBR.05015-11

Toscano G Palmerini F Ravaglia S Guillain–Barré Syndrome Associated with SARS-CoV-2 N Engl J Med. 2020 382 262574–257610.1056/NEJMc200919132302082

Tremblay L Valenza F Ribeiro SP Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model J Clin Invest. 1997 99944–952 1:CAS:528:DyaK2sXhs1Kqtbg%3D 10.1172/JCI119259

University of Mississippi Medical Center. Extra corporeal membrane oxygenation (ECMO) for COVID-19 patients (suspected or confirmed). 2020. Available from https://www.umc.edu/CoronaVirus/Mississippi-Health-Care-Professionals/Clinical-Resources/ECMO-for-COVID-19-Patients.html. Accessed 31 Jul 2020.

Valk SJ Piechotta V Chai KL Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review Cochrane Database Syst Rev. 2020 5 5CD01360010.1002/14651858.CD01360032406927

Vinetz JM Lack of efficacy of hydroxychloroquine in COVID-19 BMJ. 2020 369m201810.1136/bmj.m201832430461

Wang C Li W Drabek D A human monoclonal antibody blocking SARS-CoV-2 infection [published correction appears in Nat Commun. 2020 May 14;11(1):2511] Nat Commun 2020 11 12251 1:CAS:528:DC%2BB3cXovVChtrw%3D 10.1038/s41467-020-16256-y 32366817 7198537

Wang D Hu B Hu C Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7] JAMA. 2020 323 111061–1069 1:CAS:528:DC%2BB3cXlvVSqtbY%3D 10.1001/jama.2020.1585 32031570 7042881

Wang J Hajizadeh N Moore EE Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series J Thromb Haemost. 2020 18 71752–1755 1:CAS:528:DC%2BB3cXhtlehu7zN 10.1111/jth.1482832267998

Wang M Cao R Zhang L Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res. 2020 30 3269–271 1:CAS:528:DC%2BB3cXkt1Ciu7k%3D 10.1038/s41422-020-0282-0 32020029 32020029

Weston S , Coleman C , Haupt R , et al. Broad anticoronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo [preprint published online 25 Mar 2020]. bioRxiv. 2020.03.25.008482.

Wiedemann HP , Wheeler AP , Bernard GR , et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564–2575. https://doi.org/10.1056/NEJMoa062200.

Winkler AM Koepsell SA The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease Curr Opin Hematol. 2015 22 6521–526 1:CAS:528:DC%2BC2MXhs1Kku77F 10.1097/MOH.0000000000000191

Wu Y Xu X Chen Z Nervous system involvement after infection with COVID-19 and other coronaviruses Brain Behav Immun. 2020 8718–22 1:CAS:528:DC%2BB3cXmvFKmurw%3D 10.1016/j.bbi.2020.03.031 32240762 7146689

Ziehr DR , Alladina J , Petri CR , et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202004-1163LE.